Table 1 Univariate and multivariate analyses for OS in 39 patients with giant cells enriched GBM

Age

 < 55 years

15

1

1

 ≥ 55 years

24

2.7 (1.1–6.2)

0.019

0.2 (0.1–0.7)

0.0117

Sex

 M

26

1

 F

13

2.6 (0.9–7.2)

0.062

% Giant cells

 30–49%

15

1

 ≥ 50%

24

1.7 (0.7–4)

0.205

TP53 mutations

 No

10

1

 Yes

29

0.3 (0.1–1.2)

0.116

RB1 mutations

 No

29

1

 Yes

10

0,5 (0.2–1.4)

0.215

PTEN mutations

 No

27

1

 Yes

12

1.7 (0.5–5.1)

0.331

 CDKN2A/B homozygous deletion

 No

27

1

 Yes

12

2.2 (0.8–5.5)

0.086

EGFR amplification

 No

32

1

1

 Yes

7

6.5 (1.7–24)

0.004

3.6 (1.4–9.3)

0.007

NF1 mutations

 No

29

 Yes

10

0.5 (0.2–1.4)

0.228

TERT promoter mutations

 No

15

 Yes

24

2.2 (0.9–5.3)

0.055

Chromosome 7 gains

 No

24

 Yes

15

1.9 (0.7–4.6)

0.152

Chromosome 10 LOH

 No

16

 Yes

23

1.1 (0.4–2.7)

0.753

Hypermutation

 No

23

1

1

 Yes

16

0.3 (0.1–0.8)

0.0263

0.3 (0.1–0.8)

0.018